Select a Region

North America

Newscenter

Browsing Archive: CardiacCardiac | EVERSANA

Posted on July 30, 20247/30/24

Identifying Potential High-Risk Factor Arrhythmia Patients Using Predictive Modeling

EVERSANA

Posted on September 25, 20239/25/23

Challenges and Burdens in the Coronary Artery Disease Care Pathway for Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Narrative Review.

EVERSANA

Posted on February 1, 20232/1/23

Health impact of tafmidis in transthyretin amyloid cardiomyopathy patients: an analysis from the tafamidis in transthyretic cardiomyopathy clinical trial (ATTR-ACT) and the open-label long-term extension studies

EVERSANA

Posted on February 1, 20232/1/23

Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies

EVERSANA

Posted on February 1, 20232/1/23

Annual Cardiovascular-related Hospitalization Days Avoided With Tafamidis Treatment in Patients With Transthyretin Amyloid Cardiomyopathy

EVERSANA

Posted on February 1, 20232/1/23

Modelling Lifetime Survival Gain in Patients With Transthyretin Amyloid Cardiomyopathy and Baseline NYHA Class III: An Analysis of ATTR-ACT and Long-Term Extension Study

EVERSANA

Posted on February 1, 20232/1/23

A comparison of the costs of atrial fibrillation ablation using radiofrequency and cryoballoon technologies in the United Kingdom and Italy

Cardiac